SAVARA INC (SVRA) Stock Price, Forecast & Analysis
NASDAQ:SVRA • US8051111016
SVRA Key Statistics, Chart & Performance
The current stock price of SVRA is 5.64 USD. In the past month the price decreased by -2.42%. In the past year, price increased by 126.51%.
SVRA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SVRA. When comparing the yearly performance of all stocks, SVRA is one of the better performing stocks in the market, outperforming 92.88% of all stocks.
SVRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SVRA. SVRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SVRA Financial Highlights
Over the last trailing twelve months SVRA reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS decreased by -23.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.03% | ||
| ROE | -122.48% | ||
| Debt/Equity | 0.32 |
SVRA Forecast & Estimates
14 analysts have analysed SVRA and the average price target is 11.03 USD. This implies a price increase of 95.55% is expected in the next year compared to the current price of 5.64.
SVRA Ownership
SVRA Latest News, Press Relases and Analysis
SVRA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 403.74B | ||
| AMGN | AMGEN INC | 16.99 | 206.168B | ||
| GILD | GILEAD SCIENCES INC | 16.55 | 183.174B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.91 | 123.671B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 81.636B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.69 | 43.973B | ||
| INSM | INSMED INC | N/A | 33.829B | ||
| NTRA | NATERA INC | N/A | 29.154B | ||
| BIIB | BIOGEN INC | 12.83 | 28.637B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.386B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SVRA
Company Profile
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Langhorne, Pennsylvania and currently employs 59 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Company Info
SAVARA INC
1717 Langhorne Newtown Road, Suite 300
Langhorne PENNSYLVANIA 78746 US
CEO: Matthew Pauls
Employees: 59
Phone: 15126141848
SAVARA INC / SVRA FAQ
Can you describe the business of SAVARA INC?
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Langhorne, Pennsylvania and currently employs 59 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
What is the current price of SVRA stock?
The current stock price of SVRA is 5.64 USD. The price decreased by -1.05% in the last trading session.
Does SVRA stock pay dividends?
SVRA does not pay a dividend.
How is the ChartMill rating for SAVARA INC?
SVRA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is SVRA stock listed?
SVRA stock is listed on the Nasdaq exchange.
Should I buy SVRA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SVRA.
Who owns SAVARA INC?
You can find the ownership structure of SAVARA INC (SVRA) on the Ownership tab.